Erythema nodosum associated with infliximab therapy.
A number of unrelated cutaneous adverse events have been rarely associated with administration of infliximab. This drug has been used to control erythema nodosum when the latter was associated with Crohn disease. We herein report the paradoxical occurrence of erythema nodosum, verified by repeated challenges, following infliximab infusion given for ankylosing spondylitis. Despite this side effect, the patient elected to continue therapy due to a high degree of efficacy.
Rosen
Ted
T
Department of Dermatology, Baylor College of Medicine, Houston, TX, USA. vampireted@aol.com
Martinelli
Paul
P
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D004893:Erythema Nodosum / Q000139:chemically induced* / Q000473:pathology; D005528:Foot / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D012867:Skin / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab